Eviatar T, Ziv A, Oved A, Miller-Barmak A, et al. Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study. Vaccine 2024;42:126426.
PMID: 39423454